P.P. Bapsy

Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients

Balaswamy Reddy, V. Lokesh, M. S. Vidyasagar et al. · Oral Oncology · 2014 · 109 citations

Indian Patients, Oncology, Neoadjuvant Therapy +10

Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma

V. Kannan, P.P. Bapsy, Naranappa Anantha et al. · International Journal of Radiation Oncology*Biology*Physics · 1997 · 78 citations

Radiation Medicine, Radiation Therapy, Medicine +10

Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia

K Govind Babu, Venkata Satya Suresh Attili, P.P. Bapsy et al. · International Ophthalmology · 2007 · 54 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Ophthalmology +6

An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study.

K. Govind Babu, Lokesh Viswanath, Balaswamy Reddy et al. · Journal of Clinical Oncology · 2010 · 37 citations

Squamous Cell Carcinoma, Pathology, Crt+h-r3mab Arm +20

Irreversible sensorineural hearing loss due to Imatinib

Venkata Satya Suresh Attili, P.P. Bapsy, G. Anupama et al. · Leukemia Research · 2008 · 29 citations

Audiology, Neurotology, Human Hearing +2